Eledon pharmaceuticals announces upcoming presentation on at-1501 at the virtual 2021 international pancreas and islet transplantation association congress

Irvine, calif., oct. 05, 2021 (globe newswire) -- eledon pharmaceuticals, inc. (“eledon”) (nasdaq: eldn), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (als), announced an upcoming presentation on at-1501, its lead clinical candidate, at the international pancreas and islet transplantation association (ipita) congress, which is being held virtually from october 20-23, 2021.  an oral presentation on the use of at -1501, and pre-clinical data showing the effectiveness of at-1501 in preventing islet allograft rejection in nonhuman primate models, will be featured.
ELDN Ratings Summary
ELDN Quant Ranking